Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Beyond Air ( (XAIR) ).
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company focused on nitric oxide therapies, has brought its FDA- and CE Mark-approved LungFit PH system to market for treating hypoxic respiratory failure in term and near-term neonates. The company is targeting broader adoption of its LungFit platform in U.S. and international healthcare markets, leveraging its position in respiratory and related therapeutic segments.
On March 26, 2026, Beyond Air announced that long-serving CEO and director Steve Lisi resigned effective March 27, 2026, after nine years leading the company and overseeing the development and launch of LungFit PH. The board unanimously appointed Chief Commercial Officer and director Robert Goodman as the new CEO effective March 27, 2026, highlighting his extensive commercial experience and his role in reshaping the firm’s go-to-market strategy.
Lisi’s departure was not due to any disagreement with the company, and a separation agreement executed on March 27, 2026, provides him with 12 months of salary continuation, 12 months of COBRA coverage and accelerated vesting of all unvested equity, exercisable for 24 months. The company signaled expectations of a seamless leadership transition with no operational disruption, framing Goodman’s promotion as a move to accelerate LungFit PH market adoption, scale commercial growth and support the next phase of strategic expansion.
Goodman, a retired U.S. Army officer with more than 25 years of experience at firms including BioTelemetry, Philips Healthcare, Thermo Fisher Scientific and Pfizer, joined Beyond Air’s board in June 2025 and became Chief Commercial Officer in November 2025. As of the filing date, his existing compensation arrangements remained unchanged and the company plans to negotiate a formal CEO employment agreement, underscoring that no related-party or disclosable transactions exist involving Goodman under current regulations.
The most recent analyst rating on (XAIR) stock is a Hold with a $0.67 price target. To see the full list of analyst forecasts on Beyond Air stock, see the XAIR Stock Forecast page.
Spark’s Take on XAIR Stock
According to Spark, TipRanks’ AI Analyst, XAIR is a Neutral.
The score is held down primarily by weak financial performance (large ongoing losses, heavy cash burn, and higher leverage with reduced equity) and bearish technical trend signals (below key moving averages with negative MACD). These are partially offset by a constructive earnings update showing rapid revenue growth, a shift to gross profit, reduced expenses/cash burn, and Gen II regulatory/launch progress, though execution and FDA/inspection timing remain significant risks.
To see Spark’s full report on XAIR stock, click here.
More about Beyond Air
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company focused on harnessing endogenous and exogenous nitric oxide to treat respiratory illnesses, neurological disorders and solid tumors. Its first system, LungFit PH, has received both FDA approval and a CE Mark for treating term and near-term neonates with hypoxic respiratory failure, positioning the company in specialized inhaled nitric oxide markets.
Operating primarily in competitive healthcare sectors, Beyond Air aims to expand adoption of its LungFit franchise in U.S. and international markets. The company emphasizes technology-driven commercial execution and scaling its operations to achieve sustainable growth and enhanced value for shareholders in the inhaled nitric oxide space.
Average Trading Volume: 7,536,210
Technical Sentiment Signal: Strong Sell
Current Market Cap: $7.27M
For detailed information about XAIR stock, go to TipRanks’ Stock Analysis page.